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http://dxObjective: Calcific aortic valve disease is an active process involving a wide range of pathologic changes. Valve
interstitial cells are the most prevalent cells in the heart valve and maintain normal valve structure and function.
MicroRNAs (miRNAs) are essential posttranscriptional modulators of gene expression, and miRNA-30b is
a known repressor of bone morphogenetic protein 2–mediated osteogenesis. We hypothesized that miRNA-
30b is a multifunctional regulator of aortic valve interstitial cells during calcification.
Methods: To determine the role of miRNA-30b in calcific aortic valve disease, we evaluated miRNA expression
in human calcific aortic valve leaflets obtained intraoperatively. Furthermore, human valve interstitial cells were
evaluated with regard to miRNA-30b expression and osteogenesis by quantitative real-time polymerase chain
reaction, Western blotting, flow cytometry, and alkaline phosphatase assays.
Results: In this study, we demonstrated that miRNA-30b attenuates bone morphogenetic protein 2–induced
osteoblast differentiation by targeting Runx2, Smad1, and caspase-3. Transfection of a mimic of miRNA-30b
led to decreases in alkaline phosphatase activity and expressions of Runx2, Smad1, and caspase-3. Furthermore,
dual luciferase reporter assays confirmed that Runx2, Smad1, and caspase-3 are direct targets of miRNA-30b.
Conclusions:We demonstrated a remarkable role of miRNA-30b in calcific aortic valve disease as a regulator of
human aortic valvular calcification and apoptosis through direct targeting of Runx2, Smad1, and caspase-3.
Targeting of miRNA-30b could serve as a novel therapeutic strategy to limit progressive calcification in aortic
stenosis. (J Thorac Cardiovasc Surg 2014;147:1073-80)Supplemental material is available online.Calcific aortic valve disease (CAVD) is a major health prob-
lem threatening aging societies. Once hypothesized to be
the result of degenerative calcification, CAVD pathogenesis
is now considered to be a complex and active process char-
acterized by multiple pathologic changes.1-4 Valve
interstitial cells (VICs) are the most prevalent cells in the
heart valve and maintain normal valve structure and
function. In diseased valves, however, VICs acquire an
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blocking either cell differentiation or apoptosis may thus
be beneficial in the prevention of CAVD. Until recently,
however, the regulation of VIC function has been poorly
understood.
MicroRNAs (miRNAs) bind to the 30-untranslated region
(UTR) in specific target messenger RNAs (mRNAs) and
regulate their expression by inhibiting translation or pro-
moting target degradation.5 Recent studies have indicated
that miRNAs play an important role in osteogenic differen-
tiation.6,7 Previous experiments with MC3T3-E1 cells
showed that miRNA-30 family members function as nega-
tive regulators of osteoblastic differentiation by targeting
the master osteogenic transcription factors Smad1 and
Runx2.8 The effect of miRNA is cell type–dependent,9
however, and the specific miRNAs and target genes in-
volved in the regulation of human VIC calcification have
not been well characterized.
To illustrate the role of miRNA-30s in CAVD, we demon-
strated that miRNA-30b was the most dramatically downre-
gulated miRNA-30 family member both in pathologic
CAVD samples and in bone morphogenetic protein
(BMP) 2–stimulated aortic VICs. Our gain and loss of func-
tion experiments confirmed that by binding to multiple sites
in the 30-UTRs of Runx2, Smad1, and caspase-3 mRNAs,
miRNA-30b acts as an endogenous attenuator of these
genes in VICs to antagonize heart valve calcification.diovascular Surgery c Volume 147, Number 3 1073
Abbreviations and Acronyms
ALP ¼ alkaline phosphatase
BMP ¼ bone morphogenetic protein
CAVD ¼ calcific aortic valve disease
FBS ¼ fetal bovine serum
I-miRNA-30b ¼ microRNA-30b inhibitor
miRNA ¼ microRNA
miRNA-NC ¼ microRNA negative control
M-miRNA-30b ¼ microRNA-30b mimic
mRNA ¼ messenger RNA
qRT-PCR ¼ quantitative real-time
polymerase chain reaction
UTR ¼ untranslated region
VIC ¼ valve interstitial cell
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Reagents
Dulbecco modified Eagle medium, minimum essential medium a, and
fetal bovine serum (FBS) were purchased from Gibco (Gibco; Invitrogen
Corporation, Carlsbad, Calif). Bioactive recombinant human BMP-2,
dexamethasone, ascorbic acid, and b-glycerophosphate were purchased
from Sigma-Aldrich (Sigma, St Louis, Mo). Anti-Runx2, anti-Smad1,
anti–phosphorylated Smad1/5/8 and antiosteocalcin antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc,
Santa Cruz, Calif). Anti–caspase-3 antibody was purchased from Cell Sig-
naling Technology, Inc. (Cell Signaling Technology, Inc, Danvers, Mass).
The miRNA-30b mimic (M-miRNA-30b), the miRNA-30b inhibitor
(I-miRNA-30b), and an miRNA negative control (miRNA-NC) were syn-
thesized by GenePharma (GenePharma Co, Ltd, Shanghai, China).
Calcific Aortic Valve Collection
Calcific aortic valve samples for evaluation of miRNA expression were
collected from the 10 patients described in Table 1 who underwent aortic
valve replacement. Exclusion criteria included congenital valve disease;
nonstenotic, infective endocarditis; and rheumatic aortic valvulopathy.
The study was approved by the Changhai Hospital ethics committee, and
consent from the donors or their immediate family was obtained. After re-
section, the leaflets were sectioned into 2 parts. One part contained calcifi-
cation nodules, and the other part consisted of surrounding tissues that
served as controls. Tissues from the same patient were immediately frozen
in pairs in liquid nitrogen.
Cell Culture, Stimulation, and Transfection
Isolation of VICs. Noncalcified human aortic valves (n ¼ 10) were
taken from donor hearts during heart transplant or autopsy. Primary aortic
VICs were digested as described previously.10 In brief, nonleaflet tissues
were carefully removed after careful removal of the endothelial layer of
the aortic and ventricular aspects, and the leaflets were immersed in
0.25% trypsin at 37C for 5min. The tissues were then cut into pieces sized
approximately 3 3 3 mm for a further 2-hour digestion at 37C. The
obtained primary VICs were then cultured in growth medium (Dulbecco
modified Eagle medium supplemented with penicillin with streptomycin
and 10% FBS) at 37C under a 5% carbon dioxide atmosphere. The purity
of the cells was confirmed by microscopic examination and evaluation of
the expression of marker proteins (Figure E1).
Stimulation and transfection of VICs. The VICs (1–2 3 106
cells/well) were transfected with 50-nmol/L M-miRNA-30b, 50-nmol/L
I-miRNA-30b, and 50-nmol/L miRNA-NC in OPTI-MEMI reduced serum1074 The Journal of Thoracic and Cardiovascular Surmedium (Invitrogen) with Lipofectamine 2000 (Invitrogen) according to
the manufacturer instructions. The transfection efficiency was evaluated
in a preliminary test. Osteogenesis was further induced for 4 days after
transfection by incubation in BMP-2–supplemented osteogenesis-
inducing medium (minimum essential medium a supplemented with
0.1% FBS, 50-ng/mL BMP-2, 100-nmol/L dexamethasone, 50-mg/mL
ascorbic acid, and 5-mmol/L b-glycerophosphate). After stimulation, the
cells were harvested for further study. Cells treated with miRNA-NC or
BMP-2 served as control groups.
miRNATarget Site Prediction
A search for predicted target mRNAs was performed with the databases
TargetScan (http://www.targetscan.org), miRanda (www.miranda-im.org),
and PicTar (http://pictar.mdc-berlin.de).
Quantitative Real-Time Polymerase Chain Reaction
for Detection of miRNA-30s, Runx2, Smad1, and
Caspase-3 Expressions
For quantitative real-time polymerase chain reaction (qRT-PCR) analy-
sis, total RNAwas extracted with TRIzol (Invitrogen). SYBR Green qRT-
PCR (Takara Bio Inc, Otsu, Japan) was performed with primers published
previously (Table E1). For miRNA, qRT-PCR primers were designed and
purchased fromGene Pharma (Shanghai, China). Gene expressionwas nor-
malized to that of U6 or b-actin for miRNA and mRNA, respectively. The
expression of target genes was quantified for 6 replicates by qRT-PCR by
using One Step SYBR PrimeScript RT-PCR Kit II (Takara) on an ABI
StepOne Real-Time PCR System (Applied Biosystems; Life Technologies
Corporation, Grand Island, NY) with conventional protocols. The levels of
the target relative to the control were determined by the 2DDCT method
(http://www.appliedbiosystems.com).
Alkaline Phosphatase Activity
For alkaline phosphatase (ALP) activity assays, the treated cells were
washed twice with phosphate-buffered saline solution after incubation,
200-mL lysis buffer was added to the cell layer, and the cells were incubated
on ice for 5 minutes. The cell lysate was sonicated for 1 minutes and centri-
fuged at 1000g at 4C for 10minutes. ALPactivitywas assayed by a spectro-
photometric method. The absorbance of each well at 405 nm was measured
with a microplate reader according to the manufacturer instructions.
Western Blot Analysis
Individual cell lysates (10 mg/lane) were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes (Millipore Corporation, Billerica, Mass). After incubation
in SuperBlock T20 PBS Blocking Buffer (Thermo Fisher Scientific Inc,
Waltham,Mass), the membranes were incubated with individual antibodies
according to manufacturer instructions. The bound antibodies were de-
tected with a horseradish peroxidase–conjugated secondary antibody
diluted 1:5000 (Cell Signaling Technology), visualized with Pierce ECL
western blotting substrate (Thermo Fisher Scientific), and digitally imaged
with an enhanced chemiluminescence system.
Apoptosis Analysis With Annexin V–Fluorescein
Isothiocyanate Staining
Cells (13 106 per well) were cultured in 6-well plates to 70% to 80%
confluence. The cells were then treated with osteogenesis-inducing agents,
with or without miRNA-30b (50 nmol/L), for 96 hours. Cells were col-
lected, and the annexin V–fluorescein isothiocyanate staining assay was
performed according to the manufacturer instructions (Nanjing Keygen
Biotech, Nanjing, China). The collected cells were briefly washed in ice-
cold phosphate-buffered saline solution twice and resuspended in 300 mL
of 1X binding buffer containing 5 mL annexin Vand 5 mL propidium iodide
for 30 minutes at room temperature in the dark. After incubation, the cellsgery c March 2014
TABLE 1. Demographic and clinical characteristics of the patients
(n ¼ 10)
Parameter Value
Age (y, mean  SD) 67.7  5.14
Sex ratio (male/female) 5:5
Reason for aortic valve replacement (no.)
Valve stenosis 6
Valve stenosis and insufficiency 4
Systemic disease (no.)
Diabetes (type 2) 2
Hypertension 3
SD, Standard deviation.
Zhang et al Evolving Technology/Basic Sciencewere analyzed with a FACSCalibur cytometer (BD Becton Dickinson &
Co, San Jose, Calif).
Dual Luciferase Reporter Assay
Dual luciferase reporter gene construction. The 30-UTRs of
human genes for Runx2 (547 base pairs), Smad1 (557 base pairs), and
caspase-3 (506 base pairs) were cloned with the appropriate primers (listed
in Table E2) with a short extension containing cleavage sites for XhoI (50
end) and NotI (30 end). Amplicons were cleaved with XhoI and NotI and
cloned between the XhoI and NotI cleavage sites of the pRL-TK vector.
Luciferase assay. 293T cells were selected on the basis of low en-
dogenous expression of miRNA and grown to 85% to 90% confluence
in white 24-well plates in Dulbecco modified Eagle medium (Invitrogen)
supplemented with 10% FBS, 1% nonessential amino acids, L-glutamine,
and penicillin with streptomycin at 37C under an atmosphere with 5%
carbon dioxide. The cells were transfected with 20 ng of empty pGL3-
BASIC vector and pRL-TK-30-UTR reporter for 6 hours in reduced serum
and antibiotic-free Opti-MEM with Lipofectamine 2000. The cells were
also cotransfected with M-miRNA-30b, I-miRNA-30b, or miRNA-NC.
Firefly-luciferase and Renilla-luciferase activities weremeasured in cell ly-
sates with a Dual-Luciferase Reporter Assay System (Promega Corpora-
tion, Madison, Wis) on a Fusion plate reader (PerkinElmer Inc,
Waltham, Mass). Firefly-luciferase activity was used for normalization
and as an internal control for transfection efficiency.RESULTS
miRNA-30b Eliminated During Calcification
To determine whether miRNA-30 family members are
involved in CAVD, we evaluated the expression profile ofFIGURE 1. MicroRNA-30b (miRNA-30b) is downregulated in osteogenic va
(miRNA-30s) in calcified regions were determined by quantitative real-time po
B, MicroRNA-30b levels were significantly reduced in bone morphogenetic pr
The Journal of Thoracic and CarmiRNA-30s in surgically removed calcified aortic valves
(osteogenic markers are shown in Figure E2). Tissue adja-
cent to the calcification nodules was used as a control
(Table E3). the most notably downregulated member of
the miRNA-30 family was miRNA-30b (0.183  0.613;
Figure 1, A). To evaluate further the role of miRNA-30b
in VIC osteogenesis, VICs were treated with osteoblast-
inducing medium. The miRNA-30b expression signifi-
cantly decreased to approximately 3% of the level in the
control group (0.034  0.006; Figure 1, B). Taken together,
these results suggest that miRNA-30b plays a role in the
osteoblast differentiation of VICs in vivo as well as in vitro.Regulation by miRNA-30b of Osteogenesis in VIC
Cultures
To evaluate the impact of miRNA-30b on VIC osteoblast
differentiation, VICs were induced to differentiate into
osteoblasts after transfection with M-miRNA-30b or
I-miRNA-30b. After 4 days of osteoblast induction, the
VICs were subjected to an ALP activity assay. BMP-2 trig-
gered an artificial osteoblastic phenotype in VICs that was
characterized by ALP activation (Figure 2, A). ALP activity
(0.246  0.024 units/mg) was significantly higher in the
I-miRNA-30b group than in the blank control, BMP-2,
and miRNA-NC groups (0.027  0.001, 0.117  0.007,
and 0.111  0.012 units/mg, respectively); however, this
phenotype was obviously inhibited in VICs treated with
M-miRNA-30b (0.022  0.006 units/mg).
To confirm further the antiosteogenic effect of miRNA-
30b, we evaluated whether miRNA-30b perturbation af-
fected the level of osteocalcin expression, which is a marker
for mature osteoblasts. Relative to the other groups, trans-
fection with I-miRNA-30b resulted in increased osteocalcin
mRNA expression (4.203 0.141; Figure 2, B). In contrast,
introduction of M-miRNA-30b significantly repressed os-
teocalcin mRNA expression (1.049  0.173). Increased
osteocalcin protein levels were confirmed by immunoblot
analysis after BMP-2 treatment in VICs transfected with
I-miRNA-30b, and this effect was reversed on introductionlve interstitial cells. A, Relative expression levels of microRNA-30 types
lymerase chain reaction (n ¼ 10, mean  SD). Asterisk indicates P<.05.
otein 2 (BMP-2)–treated cells in 5 independent replications (P<.05).
diovascular Surgery c Volume 147, Number 3 1075
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FIGURE 2. MicroRNA-30b inhibits bone morphogenetic protein 2 (BMP-2) signaling–induced osteogenesis in cultured valve interstitial cells. A, Alkaline
phosphatase (ALP) activity of 5 independent experiments in each group (mean  SD). Compared with other groups, microRNA-30b inhibitor (I-miRNA-
30b) activated alkaline phosphatase to a greater extent. Asterisk indicates P<.05. B, The levels of osteocalcin messenger RNA (mRNA) were determined by
quantitative real-time polymerase chain reaction (mean  SD). Inhibition of microRNA-30b upregulated osteocalcin messenger RNA. Asterisk indicates
P<.05. C, On immunoblotting, miRNA-30b was seen to have an obvious effect on osteocalcin protein expression.miRNA-NC, microRNA negative control;
M-miRNA-30b, microRNA-30b mimic.
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M-miRNA-30b and I-miR30b sensitized the VICs to osteo-
genic signals, thus resulting in a faster or more robust
response to osteoinductive soluble factors.
Suppression by miRNA-30b of VIC Apoptosis
Apoptotic bodies are well known to act as nucleating
structures for calcium crystal formation.11 We also demon-
strated VIC degeneration in CAVD by immunohistochemi-
cal staining and terminal deoxynucleotidyl transferase
dUTP nick end labeling in sections of calcified valves
(Figure E2). To validate the assumption that miRNA-30b
in VICs may block calcification by inhibiting apoptosis,
VICs were cultured in a low-serum (0.1%) medium for
96 hours after transfection. The proportion of apoptotic
cells was quantified by annexin V–propidium iodide dual
staining. A significant increase in apoptosis was observed
in the I-miRNA-30b group (Figure 3). In contrast, the
VICs treated with M-miRNA-30b exhibited a reduced pro-
portion of apoptotic cells.
miRNA-30b Attenuates Expressions of Runx2,
Smad1, and Caspase-3
We searched for candidate genes by using the miRNA
target prediction databases Target Scan6.2 and PicTar to1076 The Journal of Thoracic and Cardiovascular Surelucidate further the relationship between miRNA-30b
and its targets during calcium nodule formation. The search
identified Runx2, Smad1, and caspase-3 as potential target
genes for miRNA-30b. Runx2 and Smad1 are widely re-
ported to be key downstream mediators of BMP-2 signaling
during bone formation.12,13 Caspase-3 is a major activated
cysteine protease reported to function in the early stage of
osteoblast proliferation.11,14,15
After 96 hours of stimulation in BMP-2–supplemented
medium, aortic VICs were evaluated for changes in target
gene expression (Figure 4). Relative to the control groups,
no effect on mRNA expression of Smad1 was observed. No-
tably, alteration inmiRNA-30b levels led to significant alter-
ation of Runx2 and caspase-3 mRNA levels (Figure 4, A).
Runx2, Smad1, phosphorylated Smad1/5/8, and caspase-3
protein levels were also altered, as demonstrated byWestern
blot analysis. In particular, the levels of these proteins
decreased in cells transfected with M-miRNA-30b and in-
creased in cells subjected tomiRNA-30b inhibition by treat-
ment with I-miRNA-30b. (Figure 4, B). Taken together, our
results provide concrete evidence that miRNA-30b nega-
tively regulates the expressions of Runx2, Smad1, and cas-
pase 3 in vitro, thereby preventing calcification of VICs.
To examine whether miRNA-30b directly regulates the
expressions of Runx2, Smad1, and caspase-3, 293T cellsgery c March 2014
FIGURE 3. MicroRNA-30b suppresses apoptosis in valve interstitial cells. Apoptotic cells are present in the upper right (early stage), and lower right (late
stage) quadrants of each panel. The most significant increase in the proportion of apoptotic valve interstitial cells was observed in cells transfected with
microRNA-30b inhibitor (I-miRNA-30b). In contrast, valve interstitial cells treated with microRNA-30b mimic (M-miRNA-30b) showed decreased apopto-
sis. BMP-2, Bone morphogenetic protein 2; miRNA-NC, microRNA negative control.
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containing the wild-type 30-UTR of each gene, and
miRNA-NC was used as the negative control. The effects
of miRNA-30b on reporter expression were determined
24 hours after transfection by measuring the Renilla-
luciferase signal normalized to firefly-luciferase. Relative
to the control cells, Renilla-luciferase activity clearly
decreased in cells transfected with M-miRNA-30b and
increased in miRNA-30b knockdown cells treated with
I-miRNA-30b (Figure 5). As expected, M-miRNA-30b sig-
nificantly inhibited the activity of the wild-type reporter
genes. These data provide evidence that miRNA-30b
inhibits the expressions of Runx2, Smad1, and caspase-3
by directly binding to distinct sites within the 30-UTRs of
their mRNAs.
DISCUSSION
In this study, we demonstrated that transfection of
M-miRNA-30b into cultured humanVICs blocks osteoblastic
transformation and apoptosis. Evaluation of the miRNA-30
profile in calcific aortic leaflets revealed a significant down-
regulation of miRNA-30b in stenotic leaflets, which was as-
sociated with increased expressions of Runx2, osteocalcin,The Journal of Thoracic and Carand caspase-3. BMP-2–treated VICs also exhibited a dra-
matic reduction in miRNA-30b level. Furthermore, an
on-off experiment suggested that in response to BMP-2,
miRNA-30b acts as an effective negative regulator of early
osteoblast differentiation through its suppression of Runx2,
Smad1, and caspase-3 expressions.
The cellular signals driving aortic valve calcification are
reminiscent of those involved in bone formation, and some
evidence suggests that the BMP-2 pathway is a central reg-
ulator of calcification in CAVD through induction of Runx2
and through the induction apoptosis.16-18 Smad1 is phos-
phorylated and activated by BMP type 1 receptor kinases
and thus participates in bone formation and cellular
apoptosis.13,19 In this study, we observed significantly
lower protein expressions of both phosphorylated Smad1/
5/8 and total Smad1 in the group treated with the
M-miRNA-30b. Consequently, both mRNA and protein
levels of Runx2 were remarkably lower than those in the
miRNA-30b knockdown (I-miRNA-30b) and control
groups, which indicates the involvement of BMP-2 signal-
ing. Caspase-3, a major activated cysteine protease of the
caspase family, is a pivotal component in the apoptotic pro-
cess,20 and it has been reported to be required fordiovascular Surgery c Volume 147, Number 3 1077
FIGURE 4. MicroRNA-30b attenuates bone morphogenetic protein 2 (BMP-2)–induced osteogenic differentiation in valve interstitial cells. Valve inter-
stitial cells were evaluated with regard to micro RNA-30b. After culture in osteogenic differentiation medium for 4 days, quantitative real-time polymerase
chain reaction and Western blotting were performed to evaluate osteogenic differentiation. A, MicroRNA-30b regulated the osteoblast markers Runx2,
Smad1, and caspase-3 at the messenger RNA (mRNA) level. Asterisk indicates P<.05. B, Western blots for Runx2, Smad1, p-Smad1, and caspase-3
were performed with the total cell lysates. miRNA-NC, microRNA negative control; M-miRNA-30b, microRNA-30b mimic; I-miRNA-30b, microRNA-
30b inhibitor.
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marrow stromal stem cells during osteogenic differentia-
tion.21 In addition, apoptosis has been reported to precede
calcification in vascular smooth muscle cells, and apoptotic
bodies derived from these cells may act as nucleating struc-
tures for calcium crystal formation.11 Caspase inhibition has
previously been shown in vitro to reduce substantially BMP-
induced ALP activation and osteogenesis.22 The role of
caspase-3 in aortic valve calcification, however, remains
poorly understood. Our qRT-PCR and Western blot data
demonstrate that transfection of M-miRNA-30b leads to1078 The Journal of Thoracic and Cardiovascular Sura reduction in caspase-3 level, whereas miRNA-30b knock-
down by I-miRNA-30b resulted in increased mRNA and
protein levels of caspase-3, relative to the expression levels
in the control cells, in addition to decreased VIC apoptosis
and ALP activity.
In cancer models, bone formation, autoimmune diseases,
and angiogenesis, miRNA-30s are widely involved in the
regulation of cell fate decisions.23-27 In blood vessels,
miRNA-30b and miRNA-30c were found to prevent vascu-
lar smooth muscle cell calcification.24 In the heart, miRNA-
30b and 6 other miRNAs showed significant differences ingery c March 2014
FIGURE 5. Runx2, Smad1, and caspase-3 are direct targets of microRNA-30b (miRNA-30b). A, Schematic representation of putative target sites for
microRNA-30b in the 30 untranslated regions (UTRs) of human Runx2, Smad1, and caspase-3 messenger RNA. B, Transfection with a micro RNA-30b
mimic (M-miRNA-30b) inhibited Renilla-luciferase activity, whereas microRNA-30b knockdown with a microRNA-30b inhibitor (I-miRNA-30b) enhanced
it. The Renilla-luciferase signal was normalized against the firefly-luciferase signal. The results are presented as the mean SD for each group of cells from
4 independent experiments. Dagger and asterisk indicate P<.05. miRNA-NC, MicroRNA negative control.
Zhang et al Evolving Technology/Basic Science
E
T
/B
Sexpression between the stenotic and insufficient bicuspid
aortic valve phenotypes.28 In this study, we first evaluated
the miRNA-30s expression profile in patients with degener-
ative calcification of the aortic valve who did not show con-
genital valve diseases. We demonstrated that among the
miRNA-30s, miRNA-30b exhibited the most dramatic re-
duction in calcific aortic valves and BMP-2–stimulated
VICs. Our gain and loss of function experiments demon-
strated decreased ALP activity and osteocalcin expression,
which may underlie an antagonizing effect of miRNA-30b
against osteoblast formation. Our findings reveal that
miRNA-30b attenuates the osteogenic differentiation ofThe Journal of Thoracic and CarVICs by directly targeting Runx2, Smad1, and caspase-3.
We demonstrated for the first time, to the best of our knowl-
edge, that Runx2, Smad1, and caspase-3 are common tar-
gets of miRNA-30b in human beings by examining direct
evidence from a dual luciferase reporter assay. In summary,
these data suggest that miRNA-30b is a negative regulator
that influences both osteocyte formation and cell apoptosis
during BMP-2–induced calcification in primary human
VICs.
Currently, surgical replacement and transcatheter implan-
tation are the only treatments for aortic stenosis in CAVD.
Improved understanding of the underlying pathogeneticdiovascular Surgery c Volume 147, Number 3 1079
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opment of targeted treatments to inhibit stenosis develop-
ment and delay or even eliminate the need for valve
replacement. Yanagawa and colleagues29 have introduced
miRNA-141 to cultured porcine VICs to block osteoblastic
transformation through a BMP-2–dependent mechanism;
however, miR-204 is reported to inhibit osteogenesis by di-
rectly targeting Runx2.6 These promising results and our
current findings indicate that miRNAs provide a tool for
fine-tuning of protein levels. In view of the indispensable
role of miRNA-30b in cellular calcification and its multiple
target genes, miRNA-30b may have potential therapeutic
applications for diseases involving VIC malfunction.
In conclusion, we have demonstrated that in response to
BMP-2, miRNA-30b negatively regulates the early calcifi-
cation of aortic VICs through suppression of Runx2,
Smad1, and caspase-3. To the best of our knowledge, this
is the first study to demonstrate in vitro a multifunctional
regulatory role of miRNA-30b in aortic VICs. Moreover,
our findings suggest that miRNA-30b maybe an effective
candidate for the prevention and treatment of aortic valve
calcification.Study Limitations
This study has some limitations. First, the mechanism un-
derlying the change in expression of miRNA-30s during
disease processes is still unknown. Second, high-quality
RNA was not reliably obtained from severely calcified
regions. Third, several other known calcium signaling path-
ways exist, and miRNAs may affect hundreds of target se-
quences, so the overall importance of the regulation of
BMP-2 by miRNA-30b remains to be explored. Finally,
our studies of miRNA-30b-mediated regulation of BMP-
2–dependent calcification in human VICs have established
a potential strategy to prevent aortic valve calcification by
targeting Runx2, Smad1, and caspase-3. Additional work
is needed to establish a causal relationship between
miRNA-30b and calcification.References
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FIGUREE1. Identification of the primary aortic valve interstitial cells. A, Microscopic analysis of cell morphology. B, The primary aortic valve interstitial
cells express specific markers (a-SMA 40%, vimentin 96%).
FIGURE E2. Histopathologic staining of the calcified aortic valves. Arrows indicate the positive immunohistochemical staining regions for Runx2 (A),
osteocalcin (B), caspase-3 (C), and terminal deoxynucleotidyl transferase dUTP nick-end labeling (D) in the high-magnification view (original magnifica-
tion 3200). Bar represents 50 mm.
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TABLE E1. Primers for quantitative real-time polymerase chain reaction
Gene Forward Reverse
b-Actin 50-AACAG CCGCCTAGAAGCAC-30 50-CGTTGACATCCGTAAAGACC-30
Runx2 50-AGCTTCTGTCTGTGCCTTCTGG-30 50-GGA GTAGA GAGGCAAGAGTT T-30
Smad1 50-TTCCATGCCTCCTCCACAAG-30 50-AGGCATTCGGCATACACCTC-30
Caspase-3 50-AGCGAATCAATGGACTCTGG-30 50-CCGAGATGTCATTCCAGTGC- 30
Osteocalcin 50-CTT TGT GTC CAA GCA GGA-30 50-CTGAAAGCCGATGTGGTCAG-30
U6 50-GTGCTCGCTTCGGCAGCACATATAC-30 50-AAAAATATGGAACGCTTCACGAATTTG-30
TABLE E2. Primers for target gene 30-UTRs
Gene Forward Reverse
Runx2 50-CTAGTCTAGACCACACCATTAGGGACCATC-30 50-ATAAGAATGCGGCCGCATCATGACCTGTGGCACAAA-30
Smad1 50-CTAGTCTAGAGCATCTGCCTCTGGAAAACT-30 50-ATAAGAATGCGGCCGCTGACAGCAAGTATGGTCAGCA-30
Caspase-3 50-CTAGTCTAGATAAATGAATGGGCTGAGCTG-30 50-ATAAGAATGCGGCCGCCAACAAGAAATCTCCCTGAA-30
TABLE E3. Measurement of microRNA-30 family in calcified valve
miRNA-30
family
DCTcalcific
regions
DCT control
segments
DDCT(DCTcalcific regions 
DCTcontrol segments)
miRNA-30a 5.37  1.92 4.68  1.91 0.69  0.37
miRNA-30b 5.86  0.47 3.31  0.63 2.55  0.62
miRNA-30c 6.11  1.30 4.99  0.92 1.12  0.47
miRNA-30d 6.63  0.85 5.30  0.71 1.33  0.49
miRNA-30e 5.72  0.79 5.43  0.69 0.30  0.20
DCT ¼ CT, target  CT, endogenous control and D(DCT) ¼ DCT, stimulated 
DCT, control. miRNA, MicroRNA.
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